Skip to main content
REGN
NASDAQ Life Sciences

Regeneron Q3 Revenue Jumps 36% to $5.1B; Non-GAAP EPS Up 70% to $20.07, Guidance Raised

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$856
Mkt Cap
$84.296B
52W Low
$591.52
52W High
$859.34
52W Position info
45% above low
Off High info
at 52W high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

REGN sits 45% above its 52-week low of $591.52.

Summary

Regeneron posted 36% revenue growth to $5.1 billion and 70% non-GAAP EPS growth to $20.07 in Q3 2026, with record Dupixent, EYLEA HD and Libtayo sales, and raised its full-year margin guidance.


Key Events · Earnings and Guidance · REGN

  • Q3 Revenue Up 36% to $5.1B

    Total revenues rose to $5,116 million from $3,754 million a year ago, with Sanofi collaboration revenue up 68% to $2,724 million.

  • Non-GAAP EPS Jumps 70% to $20.07

    GAAP diluted EPS was $18.45 (up 35%) and non-GAAP diluted EPS $20.07 (up 70%) versus $11.83 in Q3 2025.

  • Record Product Sales Across Portfolio

    Dupixent global net sales rose 35% to $6.54 billion, EYLEA HD U.S. net sales 62% to $699 million, and Libtayo global 51% to $550 million.

  • 2026 Guidance Raised on Margins

    GAAP gross margin guidance lifted to approximately 80% and non-GAAP to approximately 86%; GAAP R&D raised to $6.600-$6.735 billion while SG&A guidance was lowered.


Analysis · REGN · Life Sciences

Regeneron delivered a blowout quarter, with revenue up 36% to $5.1 billion and non-GAAP EPS up 70% to $20.07. Record Dupixent, EYLEA HD and Libtayo sales drove the top line, and the first full quarter without the Sanofi Development Balance drag added further lift. Management raised full-year gross margin guidance to roughly 80% GAAP / 86% non-GAAP and lifted R&D spend while trimming SG&A, a mix that points to operating leverage on top of top-line growth. The $1.0 billion Sanofi up-front lands in Q4 collaboration revenue, with up to $7.0 billion more in milestones. Next scheduled item: an FDA decision on cemdisiran in generalized myasthenia gravis expected next month.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, REGN was trading at $856.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.3B. The 52-week trading range was $591.52 to $859.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

REGN - Latest Insights

REGN
Nov 08, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $900.00
Real-time Price: $951.97 info
Change: +$51.97 (+6%) info
Market Cap: $98.463B info
REGN
Oct 30, 2026, 12:34 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $910.52
Real-time Price: $951.97 info
Change: +$41.45 (+5%) info
Market Cap: $98.463B info
REGN
Oct 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $835.00
Real-time Price: $951.97 info
Change: +$116.97 (+14%) info
Market Cap: $98.463B info
REGN
Oct 12, 2026, 12:06 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $764.45
Real-time Price: $951.97 info
Change: +$187.52 (+25%) info
Market Cap: $98.463B info
REGN
Oct 06, 2026, 7:51 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $721.96
Real-time Price: $951.97 info
Change: +$230.01 (+32%) info
Market Cap: $98.463B info